Taysha Gene Therapies, Inc. (TSHA) stock
TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.99−0.01 (-0.25%)
Close on Nov 18, 2026Market cap $1.30BP/E –Yield –
Taysha Gene Therapies operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Taysha Gene Therapies's operating income for the twelve months ending Jun 30, 2026 was -$153.16M. For fiscal 2025 it was -$110.50M. The highest annual figure on record is -$43.00M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$110.50M | – |
| FY2024 | Dec 31, 2024 | -$91.46M | – |
| FY2023 | Dec 31, 2023 | -$72.44M | – |
| FY2022 | Dec 31, 2022 | -$162.45M | – |
| FY2021 | Dec 31, 2021 | -$173.27M | – |
| FY2020 | Dec 31, 2020 | -$43.00M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$47.35M | – |
| Q1 FY2026 | Mar 31, 2026 | -$43.49M | – |
| Q4 FY2025 | Dec 31, 2025 | -$28.30M | – |
| Q3 FY2025 | Sep 30, 2025 | -$34.02M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.75M | – |
| Q1 FY2025 | Mar 31, 2025 | -$21.42M | – |
| Q4 FY2024 | Dec 31, 2024 | -$19.93M | – |
| Q3 FY2024 | Sep 30, 2024 | -$25.90M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.30M | – |
| Q1 FY2024 | Mar 31, 2024 | -$24.33M | – |
| Q4 FY2023 | Dec 31, 2023 | -$16.25M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.25M | – |
| Q2 FY2023 | Jun 30, 2023 | -$23.38M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.56M | – |
| Q4 FY2022 | Dec 31, 2022 | -$53.97M | – |
| Q3 FY2022 | Sep 30, 2022 | -$25.46M | – |
| Q2 FY2022 | Jun 30, 2022 | -$33.37M | – |
| Q1 FY2022 | Mar 31, 2022 | -$49.65M | – |
| Q4 FY2021 | Dec 31, 2021 | -$49.72M | – |
| Q3 FY2021 | Sep 30, 2021 | -$50.68M | – |
| Q2 FY2021 | Jun 30, 2021 | -$40.77M | – |
| Q1 FY2021 | Mar 31, 2021 | -$32.09M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.37M | – |
| Q3 FY2020 | Sep 30, 2020 | -$15.04M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.01M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.58M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.12M | – |
See a number that looks wrong?